statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Allakos Inc. (NASDAQ:ALLK  Free Report)  Equities researchers at Leerink Partnrs decreased their FY2025 EPS estimates for shares of Allakos in a research report issued to clients and...

Leerink Partnrs Research Analysts Lower Earnings Estimates for Allakos Inc. (NASDAQ:ALLK)

Allakos Inc. (NASDAQ:ALLK  Get Free Report) was the recipient of a large growth in short interest during the month of February. As of February 29th, there was short interest totalling...

Short Interest in Allakos Inc. (NASDAQ:ALLK) Increases By 9.1%

Restructuring Plan Aims to Extend Cash Runway Amid Clinical Development FocusRelated Stocks: ALLK...

Allakos Inc (ALLK) Reports Increased R&D Expenses and Net Loss in Q4

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Allakos says restructuring extends cash runway into mid-2026

Allakos reports Q4 EPS (71c), consensus (47c)

SAN CARLOS, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the Company ) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and...

Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Investors eyeing a purchase of Allakos Inc (ALLK) shares, but cautious about paying the going market price of 1.48/share, might benefit from considering selling puts among the alternative...

Commit To Buy Allakos At $1, Earn 17.9% Annualized Using Options

Shares of Allakos Inc. (NASDAQ:ALLK  Get Free Report) have earned an average rating of Hold from the seven analysts that are currently covering the company, MarketBeat Ratings...

Allakos Inc. (NASDAQ:ALLK) Given Average Rating of "Hold" by Analysts

Atopic dermatitis and prurigo nodularis skin lesions show evidence of MRGPRX2 mast cell activation and activated macrophages AK006 inhibited mast cell activation and reduced mast cell numbers...

Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024

Data provide insights on the signaling pathways involved with AK006 mast cell inhibition AK006 has a distinct mechanism of action that leads to broad inhibitory effects on mast cells SAN...

Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition

Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in San Carlos, CA.

Volume	182,038.00
52-Wk High	$5.64
52-Wk Low	$0.9799

Period	Estimated	Reported	Surprise	Result
Q1'24	-$0.44	--	--	N/A
Q4'23	-$0.47	-$0.71	-49.88%	MISSED
Q3'23	-$0.45	-$0.52	-14.99%	MISSED
Q2'23	-$0.48	-$0.41	14.58%	BEAT
Q1'23	-$0.49	-$0.49	0.48%	BEAT

ALLK Allakos Inc

About

Feed

News

Sentiment

Earnings

Fundamentals